{"disease":{"id":"metastatic-melanoma-naive-to-immune-therapy-in-metastatic-setting","name":"metastatic melanoma naive to immune therapy in metastatic setting"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03534635","title":"Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Centre Hospitalier Universitaire Vaudois","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}